All In Biotech

Drug Trial Radar · NCT00998088

Blood Management in Orthopedic Surgery

Optimal Blood Management in Elective Orthopaedic Surgery: The Transfusion "Op Maat" (TOMaat) Study

Last checked: Nov 20, 2026Latest source record: Oct 20, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,598 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,598

Actual

Start

May 2004

Primary completion

Sep 2009

Study completion Sep 2009

Sponsor

Lead sponsor
Sanquin Research & Blood Bank DivisionsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development; Roche BV Netherlands; Haemonetics Corporation
First posted
Oct 20, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Aim: to investigate whether the use of several transfusion alternatives (erythropoietin, the cell-saver or postoperative drainage and reinfusion systems) in patients undergoing elective total knee or hip replacement surgery can lead to allogeneic red blood cell (RBC) saving if a restrictive transfusion policy is used. Study design: a prospective, double randomized, open, multicenter study in which patients are stratified according to their preoperative hemoglobin(Hb) level: stratum I= Hb between 6,1 and 8,2 mmol/l. These patients are first randomized for Erythropoetin (Epo) or no Epo. Stratum II= Hb of 6,1 and lower or 8,2 mmol/l and higher, are not eligible for Epo and thus not randomized. Patients in both strata will be randomized for three modalities: a cell saver (CS)(to wash, filter and reinfuse autologous shed blood) which is used intra- and postoperatively or a postoperative autologous reinfusion drainage system (D) only (to filter and reinfuse autologous shed blood) or a restrictive transfusion trigger only (controls). Inclusion criteria: All orthopedic patients of 18 years and older being considered for a primary or revision total knee- (TKR) or total hip replacement (THR). Outcome measures: Primary outcome: number of allogeneic red blood cell (RBC) transfusions. Secondary outcome: transfusion reactions, rehabilitation time, length of hospital stay (days), peri- and post-operative complications during hospitalization, quality of life, cost analysis

Conditions

  • Osteoarthritis

Interventions

  • erythropoietin and cell saverOther

    weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion

  • erythropoietinDrug

    weekly 40.000 IU s.c. for 4 weeks pre-operatively

  • OrthoPATDevice

    for intra- and post-operative re-infusion of autologous wound blood

  • Post-operative drain deviceDevice

    For post-operative re-infusion of unwashed wound blood

  • Erythropoietin and OrthoPATOther

    weekly 40.000 IU s.c. for 4 weeks pre-operatively

  • Erythropoietin and drain deviceOther

    weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period

  • OrthoPATDevice

    For intra- and post-operative reinfusion of autologous blood

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of allogeneic red blood cell (RBC) transfusions.Time frame: up to 3 months after surgery

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Slotervaart Hospital

    Amsterdam, North Holland, Netherlands

  • Albert Schweitzer Hospital

    Dordrecht, South Holland, Netherlands

  • Groene Hart Hospital

    Gouda, South Holland, Netherlands

  • LUMC

    Leiden, South Holland, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.